Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: TREND1, conix, Phaeton, $Pistol Pete$
Search This Board: 
Last Post: 7/22/2017 12:57:55 AM - Followers: 381 - Board type: Free - Posts Today: 1


Many Afrezza users have reported rapid drops in A1c

Yeah, but in the only clinical trials that compared Afrezza to rapid acting insulins, Afrezza did no such thing.

Straight from the label:

Absolute HgA1c reduction:
Afrezza : 0.21
Rapid I : 0.40

% of patients reducing by 7% or more:
Affreza: 13.8%
Rapid I: 27.1%

And there is your problem. Tweets do not counter clinical trial data.

Afrezza avoids the needle, for sure.But is it better?

It has a faster/narrower spike. BUT, to take advantage of this, the user need to know how to use it.

Perhaps a few users have got it down, and do better. But that does not work for the masses.

MNKD really needs to figure out how to work with the new electronic glucose monitors to solve this issue.        

 p.s. Reading the Mannkind report at FDA.GOV provides plenty of clues why Afrezza is a failure.        

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MNKD News: Current Report Filing (8-k) 07/17/2017 04:47:35 PM
MNKD News: Steven Binder Joins MannKind as Chief Financial Officer 07/17/2017 09:00:00 AM
MNKD News: Notice of Effectiveness (effect) 07/17/2017 06:02:58 AM
MNKD News: Patrick McCauley Joins MannKind as Chief Commercial Officer 07/12/2017 09:00:00 AM
MNKD News: Amended Annual Report (10-k/a) 07/03/2017 06:11:17 AM
#24648  Sticky Note 1 AFREZZA uses 400% more insulin. AFREZZA drop TREND1 07/21/17 11:56:25 AM
#23743  Sticky Note $MNKD MannKind and Biomm Enter Into Distribution Agreement $Pistol Pete$ 06/01/17 01:49:35 AM
#23541  Sticky Note Buffalo teacher a key advocate in breakthrough diabetes drug Phaeton 05/19/17 12:07:29 PM
#24654 WHS 07/22/17 12:57:54 AM
#24652   DOC MARTIN TREND1 07/21/17 04:10:48 PM
#24651   Yeah disappointing, but never felt any real traction Hypi 07/21/17 01:46:12 PM
#24650   Also, the script numbers put to rest the exwannabe 07/21/17 12:46:27 PM
#24649   Rejection rate now 97.6 % for the last TREND1 07/21/17 12:11:58 PM
#24648   1 AFREZZA uses 400% more insulin. AFREZZA drop TREND1 07/21/17 11:56:25 AM
#24647   Thanks TREND1 07/21/17 10:51:40 AM
#24646   Script numbers from proboards: nobodysbusiness 07/21/17 09:00:44 AM
#24645 Hillard Saveth? WHS 07/21/17 08:13:09 AM
#24644   I would assume you have one since you TREND1 07/21/17 12:31:45 AM
#24643   Solid trade. It would have been hard tx_farmer 07/21/17 12:27:36 AM
#24642   Spencer Osborne with deeper evaluation of ad: nobodysbusiness 07/20/17 07:25:18 PM
#24641   *****MNKD trade up date TREND1 07/20/17 04:21:37 PM
#24640   Spencer Osborne, Contributor TREND1 07/20/17 10:44:10 AM
#24639   MNKD changed one of their Twitter names to Hypi 07/20/17 10:42:35 AM
#24638   Give it a few years and you'll learn nobodysbusiness 07/19/17 04:34:45 PM
#24637   I'd like to see a version of the MrLucky 07/19/17 03:35:03 PM
#24636   $MNKD Steven Binder Joins MannKind as Chief Financial $Pistol Pete$ 07/19/17 12:31:35 PM
#24635   You missed the point on the commercial, but Hypi 07/19/17 10:44:35 AM
#24634   Risingskeptic on seekingalpha reviewing commercial: nobodysbusiness 07/19/17 09:32:26 AM
#24633 WHS 07/19/17 09:21:23 AM
#24632   If you learn how to read them, charts TREND1 07/19/17 09:04:54 AM
#24631   Because CHARTS are simple are simply a record martind18 07/19/17 02:32:24 AM
#24630   I thought the cci was pointing you in jakewhite 07/18/17 11:39:51 PM
#24629   I think we all will like to know TREND1 07/18/17 10:57:33 PM
#24628   I do not know where MNKD is going. TREND1 07/18/17 10:46:19 PM
#24627   Look confusing but also looks like it's working jakewhite 07/18/17 10:44:22 PM
#24626   CCI STOCK CHARTS CHART SCHOOL TREND1 07/18/17 10:38:43 PM
#24625   Here is my current trade of MNKD TREND1 07/18/17 10:27:37 PM
#24624   I have never use a cci , it jakewhite 07/18/17 10:17:19 PM
#24623   Do not under stand your question. TREND1 07/18/17 10:13:54 PM
#24622   Hey And what does this mean buddy? jakewhite 07/18/17 10:07:39 PM
#24621   WHS D0 you have any idea where the TREND1 07/18/17 09:48:06 PM
#24620 WHS 07/18/17 09:27:25 PM
#24619   Looking at chart cci 10 is above 100 TREND1 07/18/17 09:23:34 PM
#24618   Do you have a plan to sell ? TREND1 07/18/17 08:35:29 PM
#24617   MNKD chart conix 07/18/17 08:00:16 PM
#24616   1. The negatives are already factored in to tx_farmer 07/18/17 06:45:09 PM
#24615   7/18 over BOUGHT cci 10 TREND1 07/18/17 04:18:16 PM
#24614   MNKD trade up date. TREND1 07/18/17 04:03:27 PM
#24613   Let's see a rally into the close. Tomorrow WoollenBlock48 07/18/17 02:18:06 PM
#24612   Strong pop here WoollenBlock48 07/18/17 11:08:36 AM
#24611   Even if the company is burning cash at WoollenBlock48 07/18/17 10:28:19 AM
#24610   You wouldn't necessarily conserve capital if there was nobodysbusiness 07/18/17 09:14:11 AM
#24609   You should read seekingalpha and keep up with nobodysbusiness 07/18/17 09:05:06 AM
#24608   If your scripts weren't going to jump substantially Hypi 07/18/17 02:05:54 AM
#24607   Tx farmer I am sure not worried. TREND1 07/18/17 01:16:23 AM
#24606   "Elsewhere I pointed out that apidra is in tx_farmer 07/18/17 12:10:54 AM
#24605   risingskepticism TREND1 07/17/17 11:09:24 PM
#24604   thank you and good news WHS 07/17/17 03:12:56 AM